Idera Pharma (IDRA) Reports In-Line Q2 Loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/1/2026
- Wall St set to slip as US-Iran tensions cloud start to second half
- Meta Platforms stock surges 8% on cloud business plans
- Oil falls as markets await outcome of Iran-US talks, US stocks data
- S&P 500, Nasdaq register best quarter since 2020 despite Iran war
- Dollar firm at 1-year highs as Euro Inflation cools; yen in Intervention zone
- S&P 500, Nasdaq register best quarter since 2020 despite Iran war
- Cantor Fitzgerald Starts Forward Industries (FWDI) at Overweight
- DISH DBS files prepackaged chapter 11 to repay debt, wind down wireless
- NVIDIA stock gains as SemiAnalysis sees H2 data center revenue 20% above consensus
- Boeing commercial jet deliveries and production disrupted by widespread IT outage - Air Current
Idera Pharmaceuticals Reports Second Quarter 2015 Financial Results and Provides Corporate Update
August 6, 2015 7:30 AM EDTCAMBRIDGE, Mass. and EXTON, Pa., Aug. 6, 2015 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel nucleic acid-based therapeutics for oncology and rare diseases, today reported its financial and operational results for the second quarter ended June 30, 2015.
"From a program execution perspective, we've continued to make steady progress across the board during the second quarter of 2015," stated Vincent Milano, Idera's Chief Executive Officer. "We recently announced our strategic clinical research alliance with MD Anderson, with the first planned study of this alliance... More
Idera Pharmaceuticals Reports Second Quarter 2015 Financial Results and Provides Corporate Update
August 6, 2015 7:30 AM EDTCAMBRIDGE, Mass. and EXTON, Pa., Aug. 6, 2015 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel nucleic acid-based therapeutics for oncology and rare diseases, today reported its financial and operational results for the second quarter ended June 30, 2015.
"From a program execution perspective, we've continued to make steady progress across the board during the second quarter of 2015," stated Vincent Milano, Idera's Chief Executive Officer. "We recently announced our strategic clinical research alliance with MD Anderson, with the first planned study of this alliance... More
